Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications
Authors:
Open Access
- 25 August 2020
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (4) , 2318-2332
Abstract
Retinoblastoma (RB) is a pediatric ocular tumor mostly occurring due to the biallelic loss of RB1 gene in the developing retina. Early studies of genomic aberrations in RB have provided a valuable insight into how RB can progress following the tumor‐initiating RB1 mutations and have established a notion that inactivation of RB1 gene is critical to initiate RB but this causative genetic lesion alone is not sufficient for malignant progression. With the advent of high‐throughput sequencing technologies, we now have access to the comprehensive genomic and epigenetic landscape of RB and have come to appreciate that RB tumorigenesis requires both genetic and epigenetic alterations that might be directly or indirectly driven by RB1 loss. This integrative perspective on RB tumorigenesis has inspired research efforts to better understand the types and functions of epigenetic mechanisms contributing to RB development, leading to the identification of multiple epigenetic regulators misregulated in RB in recent years. A complete understanding of the intricate network of genetic and epigenetic factors in modulation of gene expression during RB tumorigenesis remains a major challenge but would be crucial to translate these findings into therapeutic interventions. In this review, we will provide an overview of chromatin regulators identified to be misregulated in human RB among the numerous epigenetic factors implicated in RB development. For a subset of these chromatin regulators, recent findings on their functions in RB development and potential therapeutic applications are discussed.Keywords
Funding Information
- National Natural Science Foundation of China (81572764)
This publication has 105 references indexed in Scilit:
- Mechanisms and Functions of ATP-Dependent Chromatin-Remodeling EnzymesCell, 2013
- The future of epigenetic therapy in solid tumours—lessons from the pastNature Reviews Clinical Oncology, 2013
- A novel retinoblastoma therapy from genomic and epigenetic analysesNature, 2012
- Roles of the Polycomb group proteins in stem cells and cancerCell Death & Disease, 2011
- Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma GenesisCancer Cell, 2011
- Bmi1 Distinguishes Immature Retinal Progenitor/Stem Cells from the Main Progenitor Cell Population and Is Required for Normal Retinal DevelopmentStem Cells, 2010
- E2F-associated chromatin modifiers and cell cycle controlCurrent Opinion in Cell Biology, 2007
- BRG1 Chromatin Remodeling Activity Is Required for Efficient Chromatin Binding by Repressor Element 1-silencing Transcription Factor (REST) and Facilitates REST-mediated RepressionJournal of Biological Chemistry, 2006
- BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomasNucleic Acids Research, 2006
- Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste proteinGenes & Development, 2002